Trial Profile
A study evaluating renal advantages of treatment with Everolimus and Mycophenolic Acid in liver transplantation patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Oct 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Mycophenolic acid; Steroids; Tacrolimus
- Indications Liver transplant rejection
- Focus Therapeutic Use
- Acronyms CERTITUDE
- 28 Sep 2022 Results assessing long-term impact of immunosuppression (with/without a calcineurin inhibitor) on renal function, cancers, major cardiovascular events (MACEs) and other safety parameters published in the Liver International
- 12 Oct 2019 Results published in the Liver Transplantation
- 03 May 2017 Results of 1 year post transplantation, presented at the 2017 American Transplant Congress